NASDAQ:NEOSNeos Therapeutics Stock Price, Forecast & News

Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NEOS stock has decreased by 48.6% and is now trading at $0.7098. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neos Therapeutics.

Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Neos Therapeutics.

Neos Therapeutics Inc (NASDAQ:NEOS) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.06. The business earned $14.49 million during the quarter. Neos Therapeutics had a negative return on equity of 2,087.24% and a negative net margin of 26.52%. View Neos Therapeutics' earnings history.

2 analysts have issued 12 month price targets for Neos Therapeutics' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Neos Therapeutics' stock price to reach $6.50 in the next year. This suggests a possible upside of 815.8% from the stock's current price. View analysts' price targets for Neos Therapeutics.

News articles about NEOS stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neos Therapeutics earned a daily sentiment score of -3.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutNeos Therapeutics.

Neos Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,110,000 shares, an increase of 6.6% from the April 30th total of 1,980,000 shares. Based on an average daily volume of 247,700 shares, the days-to-cover ratio is currently 8.5 days. Currently, 4.3% of the shares of the stock are sold short. View Neos Therapeutics' Current Options Chain.

Some companies that are related to Neos Therapeutics include Zynerba Pharmaceuticals (ZYNE), Harrow Health (HROW), Endonovo Therapeutics (ENDV), SUMMIT THERAPEU/S (SMMT), GlycoMimetics (GLYC), Savara (SVRA), Axovant Gene Therapies (AXGT), Checkpoint Therapeutics (CKPT), AcelRx Pharmaceuticals (ACRX), InflaRx (LUMO), Theratechnologies (THERF), OASMIA PHARMACE/ADR (OASM), TapImmune (MRKR), Humanigen (HGEN) and Recro Pharma (REPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Verastem (VSTM), Exelixis (EXEL), Fibrocell Science (FCSC), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), SCYNEXIS (SCYX), Trevena (TRVN), Agile Therapeutics (AGRX) and BioDelivery Sciences International (BDSI).

(NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Neos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.43%), Sphera Funds Management LTD. (5.04%), Proxima Capital Management LLC (0.18%) and Wells Fargo & Company MN (0.17%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View institutional ownership trends for Neos Therapeutics.

NEOS stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Stonepine Capital Management LLC, and Proxima Capital Management LLC. View insider buying and selling activity for Neos Therapeutics.

NEOS stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin, and Richard I Eisenstadt. View insider buying and selling activity for Neos Therapeutics.

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NEOS stock can currently be purchased for approximately $0.71.

Neos Therapeutics has a market capitalization of $35.31 million and generates $64.65 million in revenue each year. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.

The official website for Neos Therapeutics is www.neostx.com.

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]